Top Document: misc.kids FAQ on Childhood Vaccinations, Part 3/4 Previous Document: News Headers See reader questions & answers on this topic! - Help others by sharing your knowledge From: "Mark A. Shelly"=20 >A typhoid vaccination is recommended for a trip to Costa Rica. My family >doctor said that the last time she gave someone a prescription for the >vaccine they came back with an oral vaccine. Since then she hasn't been >able to find any information comparing the oral to the injectable form: > - efficacy > - scheduling (the injectable form requires 2 doses, the first a month > before the trip) > - side effects (she says that the injectable form tends to make you feel > sick, the oral form may be an improvement). Oral typhoid vaccine is a live but weakened (attenuated) strain (Ty21a) of the Salmonella germ that causes typhoid fever. The oral vaccine is probably equal to the injected vaccine in efficacy, at about 80%. It is given orally on an empty stomach every other day for 4 doses (total elapsed time 6 days). It must be kept refrigerated but not frozen, a signif= icant limitation to use in other countries. You can't be taking antibiotics at th= e same time. It is very well tolerated. (The injected form has 80+% side effects). If yo= u have weakened immunity, or if you are too young to take pills, you shouldn'= t use this vaccine. I almost never recommend the injected form of typhoid vaccine. Typhoid vaccine is recommended for travel to areas with poor water supplies when the trip is over 3 weeks and when your eating will be "high risk". Hope this helps Mark Shelly mshelly@medicine.rochester.edu ------------------------------------------------------------------------ Typhus vaccine (not available in the US) is described by Andreas Kaunzner's= travel medicine Web site (http://members.aol.com/reisemed/impfung/typhus.htm). According to this sit= e, there are two different typhus vaccines on the market in Germany. One is a live oral vaccine, which is given in three dose= s, and gives protection for about three years, if one stays in a region where typhus is endemic; otherwise its immunity lasts for= about a year. The most common side effect, seen in fewer than 1% of those receiving the vaccine, is stomach trouble. General s= ymptoms such as fever and chills can appear, and very seldom a rash. The other is a killed vaccine, which may be given to ad= ults and children two years or older, and which provides immunity for at least three years. Its side effects are described = as "typical side effects of vaccinations" (local reactions, fever, and allergic reactions) appearing only seldom. Kabel 1 Online has a = chart of German travel vaccine recommendations (http://www.kabel1.de/reise/1998/06/26/11/) which says that typhus vaccine = is given for trips of more than three months. The CDC, on the other hand, recommends hygiene and, in areas where tick typhus = is endemic, tick removal and tick repellant; typhus vaccine production has been discontinued in the US.=20 Yellow fever is a viral infection which is spread by mosquitos. Yellow feve= r vaccine is a live vaccine which can be given only at certain vaccination centers. Many countries require this vaccination for en= try. A booster is needed every ten years. Contraindications include egg allergy and immune deficiency. Reactions are = mostly mild.=20 Vaccine components capable of causing adverse reactions: chick embryo compo= nents (Travel Medicine Advisor).=20 Travelers may also want to take anti-malarial drugs, bring insect repellant= containing N,N diethylmethylbenzamide, and avoid unboiled water, raw vegetables, fruit they haven't peeled themselves, under= cooked fish and shellfish, and food kept at room temperature. Other sources of travel health information are _Fielding's Tra= velers' Medical Companion_ and the US State Department Citizen's Emergency Center, which provides information on a vari= ety of foreign travel risks 24 hours a day at 202-647-5225. CDC Travelers' Health Section, 404-332-4559, and Immunization= Alert, 203-487-0611, have up-to-date information on vaccinations for international travel.=20 =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D Section 3n. Vaccines under development=20 [This section most recently updated on September 18, 1999. References inclu= de the Report of the Technical Review Group Meeting, 7-8 June 1998 WHO Global Program for Vaccines and Immunization Vac= cine Research and Development (http://www.who.org/gpv-documents/DocsPDF/www9845.pdf), a New England Journ= al of Medicine editorial on malaria vaccine development at http://www.nejm.org/content/1997/0336/0002/0128.asp,= reports on AIDS vaccine research at http://www.iapac.org/ and http://www.nih.gov/news/pr/may98/od-15a.htm, an I= ntellihealth report on vaccine news for 1999 (http://www.intelihealth.com/IH/ihtIH?t=3D18784&p=3D~br,IHW|~st,408|~r,WSIH= W000|~b,*|), Lon Morgan's Web site on vaccine developments: http://fp1.cyberhighway.net/~lmorgan/developments/vac= cine_development.htm, and National Institute of Health information on clinical trials at http://www.niaid.nih.gov/.]=20 Q3n.1 What vaccines are currently under development?=20 New vaccines under development include vaccines for HIV (vaccines are being= tested both to improve the immune response in those already infected and to resist infection), respiratory syncytial viru= s (Rathone), malaria, leprosy, gum disease, herpes, shigella, dengue, cervical cancer, type I diabetes, and other illnesses, as= well as an intranasal flu vaccine, new versions of the pneumococcal, meningococcal, and TB vaccines. Harrison's Internal Medicine = has a list of vaccines in human trial, and a list of those toward which priority efforts are being targetted.=20 As of May, 1998, the National Institutes of Health had evaluated 23 vaccine= candidates and 10 adjuvants (substances that might enhance the effect of a vaccine) in 49 Phase I and Phase II clinical = trials to determine the safety of the vaccine candidates and their effect on the human immune system. These studies have been conduc= ted with 2,900 volunteers. Despite all these vaccine candidates, the variation of retroviruses and the virus transmissio= n directly from cell to cell by fusion pose significant obstacles. It's anyone's guess when (and if) an AIDS vaccine will be ready.= Two articles which discuss AIDS vaccine development are "Vaccine Against AIDS?" in the British medical journal Lanc= et ((02/26/94) Vol. 343, No. 8896, P. 493) and "AIDS Vaccine: Shooting Blanks or Loaded for Bear?" in Men's Fitness ((03/9= 4) Vol. 10, No. 3, P. 118). Information about efforts to produce an AIDS vaccine is sometimes posted in sci.med.aids, and= references, updates, and current information is available by gophering to odie.niaid.nih.gov. If you have gopher, gopher od= ie.niaid.nih.gov will get you there. The AIDS FAQ (available from the pub/usenet/sci.med.aids directory of rtfm.mit.edu) desc= ribes some other Internet resources with information about AIDS.=20 When I wrote this section in 1994, I had, "The malaria vaccine has shown po= sitive results in Phase I/II trials, which were reported on February 18, 1994 issue in the British medical journal _Vaccine= _ (volume 12 no. 4, pp 328-336; 1994). (A report on an earlier trial can be found in the medical journal Lancet, volu= me 341, pp 705-710; l993). More details can also be found in a WHO press release kept on gopher.who.ch. The first results of Ph= ase III trials are expected to be available in October 1994." Unfortunately, the years since then have not seen as much pr= ogress toward a malaria vaccine as was hoped. It is known to be possible to induce immunity to malaria, as letting volunteer= s be bit by irradiated mosquitos has done so. But translating that into an effective vaccine has proved tricky. An editorial = in The New England Journal of Medicine -- January 9, 1997 -- Vol. 336, No. 2 reported that, though one vaccine has shown efficac= y, recent trials in malaria endemic areas couldn't confirm that efficacy. An improved subunit vaccine reported in the same iss= ue of NEJM, but needs to be tested in malaria endemic areas. WHO has malaria vaccine as a high priority, and aims to have= an effective and affordable vaccine within the next decade.=20 Respiratory syncytial virus (RSV) is a major respiratory pathogen among inf= ants and young children which results in an "estimated 90,000 hospitalizations among infants in the US every winter" (W= illiams, 1997). Trials have indicated that the vaccine is safe and immunogenic (produces antibodies), but there are mixed = results so far on efficacy.=20 Shigella is one of the leading causes of diarrhoeal illnesses. A shigella v= accine is moving toward clinical trials soon.=20 The vaccine for periodontitis (gum disease) has shown some positive results= in macaque monkeys (less bacterially induced bone loss in the vaccinated monkeys), indicating that a human periodontitis= vaccine is feasiable. Full-fledged clinical trials, however, may be a decade away.=20 Q3n.2 What other research is being done to improve vaccines?=20 Research is being done to improve existing vaccines (such as the research w= hich resulted in the new acellular pertussis vaccine). This includes efforts to decrease the number of visits, the numbe= r of doses, and the number of injections, to move immunization as early in life as possible (including research into the valu= e of giving vaccines to pregnant women to provide protection to infants very early in life), to decrease adverse effects, to = increase protection, and to increase thermal stability. One area being explored is whether it is possible to combine more vaccines in a= single shot. Micro-encapsulation is an attempt to encase vaccines in microcapsules which will be released over time, mimickin= g repeated injections. Trans-disease vaccinology is an attempt, by genetic engineering, to create vaccines which protect agains= t more than one disease. Efforts are also under way to produce a heat-resistant polio vaccine. (Hartveldt) (There is also a Uni= ted Press International article from 3/25/94, included in the CDC AIDS Daily Summary for March 28, 1994, which discusses the effor= t to make a vaccine which will be effective against a variety of different viruses.)=20 A major vaccine safety problem is the widespread reuse of syringes in devel= oping countries, due to scarcity, resale value, and cultural resistance to waste. In response to this problem, monodose, dispos= able vaccines, and solid, non-injected vaccines are being looked at. Solid vaccines would also eliminate the cost of keeping va= ccines cold (a major factor in vaccine delivery costs, and reduce the cost of wasted vaccines. Other research on different vaccine= delivery methods includes work on an intranasal flu vaccine and on an aerosol measles vaccine.=20 =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D=3D= =3D=3D=3D=3D Section 4. References=20 AAP recommendations (found at http://www.aap.org).=20 ACIP recommendations (found at http://www.cdc.gov/nip)=20 AMA Drug Evaluations Annual, 1993.=20 The American Medical Association Family Medical Guide. Random House, New Yo= rk. 1987.=20 The American Hospital Formulary Service Drug Information, 1992. Published b= y the American Society of Hospital Pharmacists.=20 Boughton, Clement R. "Varicella-zoster vaccine." The Medical Journal of Aus= tralia. Vol. 159. 4 October 1993.=20 California Morbidity, a Biweekly Report from the Division of Communicable D= isease Control, part of the State of California Health and Welfare Agency. Issues from October 31, 1987, May 21, 1993, and = November 19, 1993.=20 Catalana, Paul, MD. "The 'Other' Childhood Immunizations." Emergency Medici= ne, October 15, 1992. Center for Disease Control. _Health Information for International Travel_, 1992.=20 Center for Disease Control Vaccine Information Statements (found at http://= www.cdc.gov/nip).=20 Clements, C. John, Strassburg, Marc, Cutts, Felicity T. and Torel, Carol. "= The epidemiology of measles." In _World Health Statistics Quarterly, Vol 45, No 2/3, 1992.=20 FDA. "Advisory Committee Discusses Chickenpox Vaccine." January 28, 1994. (= Pulled off of fdabbs.fda.gov. Connect with login bbs to find this and other FDA information.)=20 Fettner, Ann Giuici. _The Science of Viruses._ Quill. William Morrow, New Y= ork, 1990.=20 Galazka, Artur. "Control of Pertussis in the World." In _World Health Stati= stics Quarterly_, Vol 45, No 2/3, 1992.=20 Gershon, Anna A. "Varicella - Immunization Practices in Children." Hospital= Practice. Sept. 15, 1990.=20 Ghendon, Y. "Influenza - its impact and control." In _World Health Statisti= cs Quarterly, Vol 45, No 2/3, 1992.=20 Harrison's Principles of Internal Medicine, Eleventh Edition. McGraw Hill B= ook Company, 1987.=20 Hartveldt, Frank. "The Children's Vaccine Initiative." World Health 46th ye= ar, No. 2, March-April 1993.=20 Historical Statistics of the United States, Colonial Times to 1970. Bicente= nnial Edition. US Department of Commerce, Bureau of the Census.=20 Hull, Harry F. and Ward, Nicholas A. "Progress towards the global eradicati= on of poliomyelitis." In _World Health Statistics Quarterly, Vol 45, No 2/3, 1992.=20 Journal Watch, 9-1-93. "Infant HBV Vaccination: Doubts Remain."=20 Kiple, Kenneth E., Editor. _The Cambridge World History of Human Disease_.= =20 The Lippincott Manual of Nursing Practice, Fourth Edition. 1986.=20 Mandell/Douglas/Bennett. Principles and Practice of Infectious Diseases, Th= ird Edition, 1990.=20 The Medical Letter on Drugs and Therapeutics, Vol. 34 (Issue 875), July 24,= 1992.=20 The Merck Manual, Sixteenth Edition. Merck Research Laboratories, 1992.=20 Nossal, Sir Gustav. "Prospects for new vaccines." World Health 46th year, N= o. 2, March-April 1993.=20 Onorato, Ida M., MD, Wassilak, Steven G. Md, Meade, Bruce, PhD. "Efficacy o= f Whole-Cell Pertussis vaccine in Preschool Children in the United States." JAMA, May 27, 1992, Vol. 267, No. 20.=20 Pantell, Robert H., MD, Fries, James F., MD, and Vickery, Donald M., MD. _T= aking Care of Your Child: A Parents' Guide to Medical Care._ Third Edition.=20 The Physician's Desk Reference, 1993.=20 Rathone, Mobeen H., MD. "Childhood Immunizations: An Update." Infections in= Medicine, June 1992.=20 Ryan, Frank, M.D. _The Forgotten Plague: How the Battle Against Tuberculosi= s Was Won - And Lost_. Little, Brown, and Company, 1993.=20 Shapiro, Eugene D., MD "Editorial: Pertussis Vaccines: Seeking a Better Mou= setrap." JAMA, May 27, 1992, Vol. 267, No. 20.=20 Smith, Alice Lorraine. Principles of Microbiology. The C. V. Mosby company.= St. Louis, Toronto, and London, 1992.=20 Statistical Abstracts of the United States, 1992.=20 Travel Medicine Advisor. May 1993.=20 Trollfors, B. and others. "A Placebo-Controlled Trial of a Pertussis-Toxoid= Vaccine." NEJM, Vol 333, Number 16, October 19, 1995.=20 University of California, Berkeley. _The Wellness Encyclopedia._ From the e= ditors of the UC Berkeley Wellness Letter. Houghton Mifflin Company, Boston, 1991.=20 Viral Hepatitis Prevention Board. Safety of hepatitis B vaccination program= mes. http://esoc-www.uia.ac.be/esoc/VHPB/statement.html=20 Whitman, Cynthia, Belgharbi, Lahevari, Gasse, Francois, Torel, Carol, Matte= i, Vittoria, and Zoffman, Henrik. "Progress towards the global elimination of poliomyelitis." In _World Health Statisti= cs Quarterly, Vol 45, No 2/3, 1992.=20 WHO. The Work of WHO 1990-1991. Biennial Report of the Director General.=20 Wilkerson, James A., M.D. Medicine for Mountaineering, Third Edition. The M= ountaineers, Seattle, Washington, 1985.=20 Williams, Amelia L., Ph.D. News and Perspectives: New Vaccines for Childhoo= d Immunization. Drug Benefit Trends 9(3):10-11,15-22, 1997. (Found on Medscape.)=20 Wyngaarden/Smith/Bennett. Cecil Textbook of Medicine, 19th edition, 1992.= =20 Electronic resources consulted:=20 American Association of Pediatrics Web site. http://www.aap.org=20 CDC AIDS DAILY SUMMARY (regularly posted on sci.med.aids)=20 CDC National Immunization Program Web site. http://www.cdc.gov/nip/=20 Degos, Francoise. Immunisation contre le virus de l'h=E9patite B : bilan de= quinze ann=E9es de vaccination. http://www.john-libbey-eurotext.fr/articles/aB80DA9A7/index.htm=20 fdabbs.fda.gov (login using name "bbs") (more recently, http://www.fda.gov)= =20 gopher.who.ch (gopher gopher.who.ch, also:=20 telnet gopher.who.ch login:gopher) (more recently, http://www.who.org)=20 HICNet Medical News Digest (available from LISTSERV@ASUACAD.BITNET; regular= ly posted to sci.med)=20 Immunization Action Coalition Web site. http://www.immunize.org=20 Journal Watch Summaries (regularly posted to sci.med by jwatch@world.std.co= m)=20 Le point sur la vaccination contre l'h=E9patite B http://www.sante.gouv.fr/= htm/pointsur/vaccins/effets_sec_hep_b.htm=20 Levy-Bruhl, Daniel et al. Comparaison entre les Risques de Premieres Attein= tes Demyelinisantes Centrales Aigues et les Benefices de la Vaccination Contre L'Hepathite B. http://www.rnsp-sante.fr/= beh/1999/9909/index.html=20 Medscape http://www.medscape.com=20 Also available on the net is the Morbidity and Mortality Weekly Report (MMW= R). It is available by Worldwide Web at:=20 http:/www.cdc.gov/; Go to publications and scientific data, then Morbidity = and Mortality Weekly Report, OR=20 by gopher at Duke University.=20 Morgan, Lon. Immunization, Vaccines, Vaccination in the Modern World http:/= /fp1.cyberhighway.net/~lmorgan/=20 Swiss Medical Weekly. http://www.smw.ch=20 A list of Internet and Bitnet Health Sciences resources, compiled by Lee Ha= ncock, can be ftped from the pub/nic directory of ftp.sura.net.=20 User Contributions: 1 ytnlfq ⚠ May 7, 2022 @ 1:01 am side effects of hydroxychlor 200 mg https://keys-chloroquinehydro.com/ Comment about this article, ask questions, or add new information about this topic:Top Document: misc.kids FAQ on Childhood Vaccinations, Part 3/4 Previous Document: News Headers Part1 - Part2 - Part3 - Part4 - Single Page [ Usenet FAQs | Web FAQs | Documents | RFC Index ] Send corrections/additions to the FAQ Maintainer: lynng@alsirat.com
Last Update March 27 2014 @ 02:11 PM
|